NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma
Neri L (1), Lasa M (1), Elosegui-Artola A (2), D'Avola D (3,4), Carte B (1), Gazquez C (1), Alve S (5), Roca-Cusachs P (2,6), Iñarrairaegui M (3,4), Herrero J (3,4), Prieto J (1,3), Sangro B (3,4), Aldabe R (1,4).
(1) Gene Therapy and Regulation of Gene Expression Program, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Spain.
(2) Institute for Bioengineering of Catalonia, Barcelona, Spain.
(3) Liver Unit, Clínica Universidad de Navarra, Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (Ciberehd), Pamplona, Spain.
(4) Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
(5) Department of Biology, CBMA-Centre of Molecular and Environmental Biology, University of Minho, Campus de Gualtar, Braga, Portugal.
(6) University of Barcelona, Barcelona, Spain.
The identification of new targets for systemic therapy of hepatocellular carcinoma (HCC) is an urgent medical need. Recently, we showed that hNatB catalyzes the N-α-terminal acetylation of 15% of the human proteome and that this action is necessary for proper actin cytoskeleton structure and function. In tumors, cytoskeletal changes influence motility, invasion, survival, cell growth and tumor progression, making the cytoskeleton a very attractive antitumor target.
Here, we show that hNatB subunits are upregulated in in over 59% HCC tumors compared to non-tumor tissue and that this upregulation is associated with microscopic vascular invasion. We found that hNatB silencing blocks proliferation and tumor formation in HCC cell lines in association with hampered DNA synthesis and impaired progression through the S and the G2/M phases.
Growth inhibition is mediated by the degradation of two hNatB substrates, tropomyosin and CDK2, which occurs when these proteins lack N-α-terminal acetylation. In addition, hNatB inhibition disrupts the actin cytoskeleton, focal adhesions and tight/adherens junctions, abrogating two proliferative signaling pathways, Hippo/YAP and ERK1/2.
Therefore, inhibition of NatB activity represents an interesting new approach to treating HCC by blocking cell proliferation and disrupting actin cytoskeleton function.
CITA DEL ARTÍCULO Oncotarget. 2017 Apr 21. doi: 10.18632/oncotarget.17332